[
  {
    "info": {
      "NCT": "NCT05503797",
      "jit": "Caris",
	"Protocol_No": "F8394-201a F8394-201b",
      "trial_name": "Fore Biotherapeutics F8394-201a F8394-201b"
    },
    "disease": {
      "summary": "locally advanced or metastatic solid tumors |  recurrent or progressive primary central nervous system (CNS)  |  recurrent high-grade glioma (HGG)",
      "details": [
        {
          "code": "CNS/Brain (BRAIN)",
          "selection": "include"
        },
        {
          "code": "Anaplastic Astrocytoma (AASTR)",
          "selection": "include"
        },
        {
          "code": "Anaplastic Oligoastrocytoma (AOAST)",
          "selection": "include"
        },
        {
          "code": "Anaplastic Oligodendroglioma (AODG)",
          "selection": "include"
        },
        {
          "code": "High-Grade Glioma, NOS (HGGNOS)",
          "selection": "include"
        },
        {
          "code": "Astrocytoma (ASTR)",
          "selection": "include"
        },
        {
          "code": "Anaplastic Pleomorphic Xanthoastrocytoma (APXA)",
          "selection": "include"
        },
        {
          "code": "Encapsulated Glioma (ENCG)",
          "selection": "include"
        },
        {
          "code": "Pilocytic Astrocytoma (PAST)",
          "selection": "include"
        },
        {
          "code": "Gliosarcoma (GSARC)",
          "selection": "include"
        },
        {
          "code": "Glioblastoma (GB)",
          "selection": "include"
        }
      ]
    },
    "query": {
      "nct": "NCT05503797",
      "title": "A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations",
      "current_status": "Not yet recruiting",
      "status_verif_date": "October 2022",
      "last_update_date": "October 19, 2022",
      "trial_hold_status": "open",
      "sponsor": "Fore Biotherapeutics",
      "brief_summary": "The objective of this study is to evaluate the efficacy of FORE8394 in participants with locally advanced or metastatic solid tumors, or recurrent or progressive primary central nervous system (CNS) tumors harboring BRAF fusions, or in participants with recurrent high-grade glioma (HGG) harboring BRAF V600E mutation. This will be conducted as two single arm open-label subprotocols (F8394-201A; F8394-201B) under one master protocol.",
      "conditions": "Cancer Harboring BRAF Alterations",
      "type": "Interventional",
      "phase": "Phase 2",
      "arm": [
        {
          "ArmID": "1",
          "cohortlabel": "Group A",
          "drug": "FORE8394 | Cobicistat",
          "arm_type": "Experimental",
          "line_of_therapy": "2",
          "arm_hold_status": "open",
          "biomarker": [
            {
              "cohort": "Group A",
              "Gene": "BRAF",
              "Gene2": "Not available",
              "Type": "Fusion",
             "Variant": "V600E",
              "Selection": "include",
              "Function": "Not available",
              "summary": "BRAF Gene Fusion  "
            },
            {
              "cohort": "Group A",
              "Gene": "NF1",
              "Gene2": "Not available",
              "Type": "Alteration",
              "Variant": "Not available",
              "Selection": "exclude",
              "Function": "Not available",
              "summary": "NF1 Alteration  "
            },
            {
              "cohort": "Group A",
              "Gene": "KRAS",
              "Gene2": "Not available",
              "Type": "Alteration",
              "Variant": "Not available",
              "Selection": "exclude",
              "Function": "Not available",
              "summary": "RAS Alteration  "
            }

          ]
        },
        {
          "ArmID": "2",
          "cohortlabel": "Group B",
          "drug": "FORE8394 | Cobicistat",
          "arm_type": "Experimental",
          "line_of_therapy": "2",
          "arm_hold_status": "open",
          "biomarker": [
            {
              "cohort": "Group B",
              "Gene": "BRAF",
              "Gene2": "Not available",
              "Type": "Mutation",
              "Variant": "V600E",
              "Selection": "include",
              "Function": "Not available",
              "summary": "BRAF V600E Mutation  "
            },
            {
              "cohort": "Group B",
              "Gene": "NF1",
              "Gene2": "Not available",
              "Type": "Alteration",
              "Variant": "Not available",
              "Selection": "exclude",
              "Function": "Not available",
              "summary": "NF1 Alteration  "
            },
            {
              "cohort": "Group B",
              "Gene": "KRAS",
              "Gene2": "Not available",
              "Type": "Alteration",
              "Variant": "Not available",
              "Selection": "exclude",
              "Function": "Not available",
              "summary": "RAS Alteration  "
            }
          ]
        }
      ],
      "docs": "https://trialplus.carisls.com ",
      "min_age": "10 Years",
      "gender": "All",
      "link": "<a href=\"https://clinicaltrials.gov/ct2/show/NCT05503797\" target=\"_blank\">NCT05503797<\/a>"
    }
  }
]
